Notice of Special Interest (NOSI): Availability of Emergency Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs

Funding Agency:
National Institutes of Health

The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts.

NCATS is soliciting applications for Administrative Supplements (through PA-20-272) from current Clinical and Translational Science Award (CTSA) UL1 component award recipients from these FOAs:

  • PAR-18-940 Clinical and Translational Science Award (U54 Clinical Trial Optional)
  • PAR-18-464 Clinical and Translational Science Award (U54 Clinical Trial Optional)
  • PAR-15-304 Clinical and Translational Science Award (U54 Clinical Trial Optional)
  • RFA-TR-14-009 Clinical and Translational Science Award (U54 Clinical Trial Optional)

NCATS expects to issue 2-9 awards (anticipated to be $30,000 to $60,000 Direct Costs) for provision of clinical data in specified formats to support illness/infection status/surveillance determinations and/or clinical study data.

Applications will be accepted immediately and on a rolling basis through June 1, 2021 by 5:00 PM local time of the applicant organization. This NOSI expires on June 2, 2021. An application submitted in response to this NOSI that is received on June 2, 2021 or later, will be withdrawn. Applications will be considered for funding in FY21 pending: award timelines, availability of funds, and programmatic priority.

NOT-TR-21-011

Eligibility

Faculty

Category

Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

June 1, 2021